Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Apellis Pharmaceuticals Inc (APLS)  
$49.86 1.93 (4.03%) as of 4:30 Fri 4/26


Download
   
Exchange: N/A
Security Type: Common
Shares Out: 114,470,000
Market Cap: 5.71(B)
Last Volume: 0 Avg Vol: 0
52 Week Range: $23.65 - $93.31
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of therapeutic compounds to treat disease through the inhibition of the complement system at the level of C3. Co.'s primary product candidate, pegcetacoplan, is a conjugate of a compstatin analogue, formulated both for intravitreal administration by injections directly into the eye, and systemic administration by subcutaneous injection, which is an injection into the tissue under the skin. Co. is also developing APL-9 for the prevention of complement immune system activation coincident with adeno-associated virus vector administration for gene therapies and other indications.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 457,416 731,314 982,251 1,465,940
Total Sell Value $28,239,469 $44,833,615 $62,961,973 $91,607,995
Total People Sold 11 14 14 16
Total Sell Transactions 26 62 85 159
End Date 2024-01-28 2023-10-27 2023-04-28 2022-04-28

   
Records found: 714
  Page 1 of 29  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Sullivan Timothy Eugene Chief Financial Officer   •       –      –    2024-04-18 4 GA $0.00 $0 I/I 14,164 70,396     -
   Sullivan Timothy Eugene Chief Financial Officer   •       –      –    2024-04-18 4 GD $0.00 $0 D/D 14,164 79,174     -
   Dunlop A. Sinclair Director   •       •      –    2024-04-12 4 OE $13.19 $19,785 D/D 1,500 133,518     -
   Deschatelets Pascal Chief Scientific Officer   •       •      –    2024-04-08 4 AS $54.12 $3,743,605 D/D (69,107) 1,115,983 -12%     
   Deschatelets Pascal Chief Scientific Officer   •       •      –    2024-04-08 4 OE $3.76 $259,842 D/D 69,107 1,185,090     -
   Sullivan Timothy Eugene Chief Financial Officer   •       •      –    2024-04-01 4 AS $58.66 $234,640 D/D (4,000) 93,338 -20%     
   Sullivan Timothy Eugene Chief Financial Officer   •       •      –    2024-04-01 4 OE $10.03 $40,120 D/D 4,000 97,338     -
   Dunlop A. Sinclair   –       •      –    2024-03-19 4 S $57.18 $1,068,161 I/I (18,681) 173,998 16%     
   Delong Mark Jeffrey Chief Business & Strat Officer   •       •      –    2024-03-18 4 S $56.90 $564,050 D/D (9,913) 54,693 15%     
   Chopas James George VP/Chief Accounting Officer   •       •      –    2024-03-15 4 S $56.46 $10,389 D/D (184) 38,883 16%     
   Nicholson Nur Chief Technical Officer   •       •      –    2024-03-13 4 S $57.31 $645,838 D/D (11,220) 56,287 16%     
   Deschatelets Pascal Chief Scientific Officer   •       •      –    2024-03-08 4 AS $61.88 $4,297,549 D/D (69,107) 1,115,983 -23%     
   Deschatelets Pascal Chief Scientific Officer   •       •      –    2024-03-08 4 OE $3.67 $253,623 D/D 69,107 1,185,090     -
   Watson David O. General Counsel   •       •      –    2024-03-06 4 OE $13.85 $52,104 D/D 3,762 107,152     -
   Sullivan Timothy Eugene Chief Financial Officer   •       •      –    2024-03-01 4 AS $62.86 $379,340 D/D (6,000) 93,338 -26%     
   Sullivan Timothy Eugene Chief Financial Officer   •       •      –    2024-03-01 4 OE $10.03 $60,180 D/D 6,000 99,338     -
   Francois Cedric Chief Executive Officer   •       •      –    2024-03-01 4 AS $62.21 $16,028,706 D/D (250,000) 313,662 -26%     
   Francois Cedric Chief Executive Officer   •       •      –    2024-03-01 4 OE $3.76 $1,050,000 D/D 250,000 563,662     -
   Delong Mark Jeffrey Chief Business & Strat Officer   •       •      –    2024-02-12 4 S $67.77 $40,457 D/D (597) 64,606 29%     
   Francois Cedric Chief Executive Officer   •       •      –    2024-02-12 4 S $67.77 $268,492 D/D (3,962) 313,662 29%     
   Deschatelets Pascal Chief Scientific Officer   •       •      –    2024-02-12 4 S $67.77 $77,796 D/D (1,148) 1,115,983 29%     
   Townsend Adam J. Chief Commercial Officer   •       •      –    2024-02-12 4 S $67.77 $77,796 D/D (1,148) 92,453 29%     
   Watson David O. General Counsel   •       •      –    2024-02-12 4 S $67.77 $52,926 D/D (781) 103,390 29%     
   Sullivan Timothy Eugene Chief Financial Officer   •       •      –    2024-02-12 4 S $67.77 $96,974 D/D (1,431) 93,338 29%     
   Eisele Jeffrey Chief Development Officer   •       •      –    2024-01-30 4 AS $65.53 $63,630 D/D (971) 57,208 -28%     
  714 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 1 of 29
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us